Overcoming therapy resistance in EGFR-mutant lung cancer

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on...

Full description

Saved in:

Bibliographic Details
Published in:	Nature cancer Vol. 2; no. 4; pp. 377 - 391
Main Authors:	Passaro, Antonio, Jänne, Pasi A, Mok, Tony, Peters, Solange
Format:	Journal Article
Language:	English
Published:	England 01-04-2021
Subjects:	Carcinoma, Non-Small-Cell Lung - drug therapy Drug Resistance, Neoplasm - genetics ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Mutation Protein Kinase Inhibitors - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as current and future efforts to define treatment strategies to overcome resistance.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2662-1347 2662-1347
DOI:	10.1038/s43018-021-00195-8